VERA insider transaction filings
Vera Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-17. Screen VERA transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 9 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 16 legs across 7 filings by 1 insider — 185,000 shares, $7,329,802 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 32,550 shares @ $42.07 ($1,369,496) by Fordyce Marshall, filed 2026-08-12.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Fordyce Marshall — PRESIDENT AND CEO, Director | 7 | — | 16 legs · 185,000 sh · $7,329,802 | 10 |
| Boman Nancy Lee — Chief Regulatory Officer | 1 | — | — | 2 |
| Young Joseph R — SVP, FINANCE, CHIEF ACCT OFFCR | 1 | — | — | 2 |
Recent Form 4 filings — Vera Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Fordyce Marshall — PRESIDENT AND CEO, Director | Option exercise (M): 18,500 @ $2.90 · Sale (S): 18,500 @ $37 · Option exercise (M): 18,500 (derivative) @ $0 | EDGAR |
| 2026-09-14 | 4 | Young Joseph R — SVP, FINANCE, CHIEF ACCT OFFCR | Option exercise (M): 5,000 @ $3.94 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-09-04 | 4 | Fordyce Marshall — PRESIDENT AND CEO, Director | Option exercise (M): 18,500 @ $2.90 · Sale (S): 18,500 @ $35.12 · Option exercise (M): 18,500 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4/A | Fordyce Marshall — PRESIDENT AND CEO, Director | Option exercise (M): 46,250 @ $2.90 · Sale (S): 1,000 @ $40.78 · Sale (S): 32,550 @ $42.07 · Sale (S): 10,500 @ $42.86 · Sale (S): 2,200 @ $43.59 · Option exercise (M): 46,250 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4/A | Fordyce Marshall — PRESIDENT AND CEO, Director | Option exercise (M): 18,500 @ $2.90 · Sale (S): 14,219 @ $36.64 · Sale (S): 4,281 @ $37.09 · Option exercise (M): 18,500 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4/A | Fordyce Marshall — PRESIDENT AND CEO, Director | Option exercise (M): 18,500 @ $2.90 · Sale (S): 18,412 @ $37.93 · Sale (S): 88 @ $38.43 · Option exercise (M): 18,500 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Boman Nancy Lee — Chief Regulatory Officer | Grant/award (A): 44,987 @ $0 · Grant/award (A): 63,011 (derivative) @ $0 | EDGAR |
| 2026-07-09 | 4 | Fordyce Marshall — PRESIDENT AND CEO, Director | Sale (S): 1,000 @ $40.78 · Sale (S): 32,550 @ $42.07 · Sale (S): 10,500 @ $42.86 · Sale (S): 2,200 @ $43.59 | EDGAR |
| 2026-06-24 | 4 | Fordyce Marshall — PRESIDENT AND CEO, Director | Sale (S): 18,412 @ $37.93 · Sale (S): 88 @ $38.43 | EDGAR |
| 2026-05-26 | 4 | Hall Kimball — Director | Grant/award (A): 17,084 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Oliger Christy J. — Director | Grant/award (A): 17,084 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Cheng Andrew — Director | Grant/award (A): 17,084 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Morrison Scott W — Director | Grant/award (A): 17,084 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Meyers James R — Director | Grant/award (A): 17,084 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | ENRIGHT PATRICK G — Director | Grant/award (A): 17,084 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | MORRISSEY MICHAEL — Director | Grant/award (A): 17,084 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | SEIDENBERG BETH C — Director | Grant/award (A): 17,084 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | Fordyce Marshall — PRESIDENT AND CEO, Director | Sale (S): 14,219 @ $36.64 · Sale (S): 4,281 @ $37.09 | EDGAR |
| 2026-04-15 | 4 | Fordyce Marshall — PRESIDENT AND CEO, Director | Sale (S): 14,130 @ $43.66 · Sale (S): 7,921 @ $44.58 · Sale (S): 900 @ $45.51 | EDGAR |
| 2026-03-25 | 4 | Wright-Mitchell Jane — Chief Legal Officer | Grant/award (A): 42,403 @ $0 · Grant/award (A): 56,850 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Young Joseph R — SVP, FINANCE, CHIEF ACCT OFFCR | Option exercise (M): 10,000 @ $3.94 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Hite Christopher — Director | Grant/award (A): 24,937 (derivative) @ $0 | EDGAR |
| 2026-02-25 | 4 | Skelton Laurence Matthew — Chief Commercial Officer | Sale (S): 1,582 @ $41.98 | EDGAR |
| 2026-02-25 | 4 | Brenner Robert — Chief Medical Officer | Sale (S): 2,151 @ $41.98 | EDGAR |
| 2026-02-25 | 4 | Grant Sean — CHIEF FINANCIAL OFFICER | Sale (S): 4,949 @ $41.98 | EDGAR |
| 2026-02-25 | 4 | Young Joseph R — SVP, FINANCE, CHIEF ACCT OFFCR | Sale (S): 3,117 @ $41.98 | EDGAR |
| 2026-02-25 | 4 | Fordyce Marshall — PRESIDENT AND CEO, Director | Sale (S): 16,925 @ $41.98 | EDGAR |
| 2026-02-25 | 4 | Turner William D. — Chief Regulatory Officer | Sale (S): 2,187 @ $41.98 | EDGAR |
| 2026-02-25 | 4 | JOHNSON DAVID LEE — Chief Operating Officer | Sale (S): 2,579 @ $41.98 | EDGAR |
| 2026-02-06 | 4 | Skelton Laurence Matthew — Chief Commercial Officer | Grant/award (A): 20,000 @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Brenner Robert — Chief Medical Officer | Grant/award (A): 25,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Grant Sean — CHIEF FINANCIAL OFFICER | Grant/award (A): 25,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Young Joseph R — SVP, FINANCE, CHIEF ACCT OFFCR | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Fordyce Marshall — PRESIDENT AND CEO, Director | Grant/award (A): 68,800 @ $0 · Grant/award (A): 137,500 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Turner William D. — Chief Regulatory Officer | Grant/award (A): 25,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | JOHNSON DAVID LEE — Chief Operating Officer | Grant/award (A): 20,000 @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | Turner William D. — Chief Regulatory Officer | Option exercise (M): 10,000 @ $15.53 · Sale (S): 10,000 @ $50.08 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | ENRIGHT PATRICK G — Director | Purchase (P): 5,882 @ $42.50 | EDGAR |
| 2025-12-10 | 4 | Turner William D. — Chief Regulatory Officer | Option exercise (M): 10,000 @ $15.53 · Sale (S): 10,000 @ $45.31 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-12-04 | 4 | Turner William D. — Chief Regulatory Officer | Option exercise (M): 10,000 @ $15.53 · Sale (S): 10,000 @ $40 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-11-26 | 4 | Meyers James R — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Carter Jason S — Chief Legal Officer | Sale (S): 3,864 @ $27.82 | EDGAR |
| 2025-11-13 | 4 | Young Joseph R — SVP, FINANCE, CHIEF ACCT OFFCR | Sale (S): 15,000 @ $29.06 · Option exercise (M): 10,000 @ $3.94 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | ENRIGHT PATRICK G — Director | Purchase (P): 69,798 @ $20.87 · Purchase (P): 139,595 @ $20.87 · Purchase (P): 13,536 @ $22.35 · Purchase (P): 27,071 @ $22.35 | EDGAR |
| 2025-05-16 | 4 | Cheng Andrew — Director | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Katabi Maha — Director | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Morrison Scott W — Director | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | ENRIGHT PATRICK G — Director | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | MORRISSEY MICHAEL — Director | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | SEIDENBERG BETH C — Director | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Vera Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-15 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-07-07 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-02 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-26 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VERA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →